Biography
Eric N. Marton has 25+ years of experience in healthcare and currently serves as Managing Director at Three-Sixty Advisory Group and Venture Partner at Wavemaker 360 Health. Prior to this, Eric was recruited by private equity firm BlueMountain Capital to serve as Chief Strategy Officer of Verity Health – with six hospital campuses and numerous ambulatory centers. Concurrently, Eric was CEO of the Verity Physician Network and CEO of Verity subsidiary, Surgical Partners of California. Eric’s other past positions include Executive Director at Cedars-Sinai Health System, CEO of the California Heart Center at UCLA, and Managing Partner at Catalyst Venture Group.

Biography
For over 30 years Dr. Markman has been engaged in clinical research in the area of gynecologic malignancies. Dr. Markman has been the primary author or co-author on over 1,000 published peer-reviewed manuscripts, reviews, book chapters, editorials or abstracts, and has written, edited or co-edited 23 books on various topics in the management of malignant disease. In 2011, Dr. Markman received the American Society of Clinical Oncology (ASCO) Statesman Award, which recognizes individual members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years. In May, 2018, Dr. Markman was named by OncLive® to an elite group of the 2018 Giants of Cancer Care® recognition program which celebrates pioneers, innovators and leaders who have made remarkable achievements in oncology research and clinical practice. Dr. Markman was selected in recognition of his contributions in gynecologic cancers.

Biography
Dr. Vial is a practicing cardiac surgeon who also serves as the Chief Physician Executive of Operations for Sutter Health and sits on the system’s Operations Leadership Team (OLT), chaired by Sutter Health’s Chief Operating Officer. In his leadership role, Dr Vial acts as a principal author of clinical strategy deployment, responsible for unifying clinical program building, business development, and operational efficiency across the continuum of care. An important focus of his work is the extension of ongoing specialty service line integration efforts, informing not only operations but also analytics and innovation through interdisciplinary clinical leadership platforms. From the clinical practice perspective, Dr. Vial is particularly interested in structural heart disease, focusing on minimally invasive cardiothoracic surgery and catheter-based valve repair/replacement. He received his bachelor’s degree and medical doctorate from Stanford University. In addition, Dr. Vial earned a master’s of philosophy at Cambridge University in England, while also completing a postdoctoral fellowship in transplant immunology. He received his general surgical and cardiothoracic surgical training at Stanford University Medical Center.

Biography
Farid Vij is Vice President of Corporate Development at Ciitizen where he drives the company’s go-to-market strategy and engagements with partners including patient advocacy organizations, providers and biotech/biopharma. Farid’s focus is on creating a scalable model that allows advocacy partners and patients to garner value through sharing their health data yet retaining control of it at all times. He believes there is a sustainable way to drive patient-driven research by ensuring patients always gain benefit through their participation. Prior to Ciitizen, Farid was Global Head of Sales & Business Development at ZL Technologies where he led the development and launch of ZL’s Big Data cloud business to support legal compliance with GDPR and built a global sales and marketing organization across four regions. Farid received a B.S. in Economics from the Wharton School at the University of Pennsylvania.

Biography
June Wasser currently serves as a consultant to organizations on health science policy and engagement. As former Executive Director of the Reagan-Udall Foundation for the FDA she provided leadership for the Foundation’s development of initiatives intended to foster advances in regulatory science in support of the FDA’s mission. Ms. Wasser built strategic relationships throughout the public and private sectors with the goal of developing a portfolio of unique programs that complement and enhance the priorities and activities of the FDA such as: Innovations in Medical Evidence Development and Surveillance which serves to advance the science necessary to support post-market evidence generation on regulated products and an Expanded Access Navigator that aims to increase knowledge around the use of patient access to investigational drugs for patients facing life-threatening illnesses. She also created the Innovations in Regulatory Science Awards program to recognize leaders in the regulatory field.